Citius Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CTXR Nasdaq 2830 citiuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Citius Pharmaceuticals, Inc.

Citius Oncology Announces Closing of $9.0 Million Public Offering - Jul 17th, 2025 2:30 pm
Citius Oncology Announces Pricing of $9.0 Million Public Offering - Jul 16th, 2025 7:15 am
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - Jul 15th, 2025 6:32 am
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - Jul 8th, 2025 6:34 am
Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR - Jul 6th, 2025 2:01 am
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 - Jun 17th, 2025 6:08 am
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - Jun 12th, 2025 6:35 am
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - Jun 10th, 2025 5:00 am
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health - Jun 9th, 2025 6:37 am
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - May 14th, 2025 2:30 pm
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - May 5th, 2025 6:37 am
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Apr 1st, 2025 7:00 am
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services - Feb 6th, 2025 6:55 am
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Jan 8th, 2025 6:00 am
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - Jan 7th, 2025 6:08 am
Citius Oncology to explore strategic alternatives - Jan 7th, 2025 5:57 am
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - Jan 6th, 2025 5:50 am
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Dec 31st, 2024 5:10 am
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls - Dec 30th, 2024 7:43 am
Citius Pharma Reports 2024 Financial Results and Business Update - Dec 29th, 2024 8:50 pm